PROTOX APPOINTS NEW DIRECTORS

 VANCOUVER, Feb. 22 /CNW/ - Protox Therapeutics Inc. (the "Company" or  "Protox") (TSX: PRX), a leader in the development of receptor targeted  therapeutic fusion proteins, is pleased to announce the appointment of  Mr. William Rohn and Mr. Amit Sobti to the Company's Board of  Directors.  "We are delighted to welcome Bill and Amit to help guide Protox through  the exciting phase of the company's progress," said Dr. Fahar Merchant,  President & CEO of Protox. "Their insights and experience with product  commercialization and the capital markets from both the large  pharmaceutical arena and the biotech industry will be invaluable. Their  appointment is just another indication of our commitment to build and  strengthen our board and to enhance our ability to move the company to  the next level."  Bill Rohn has over 30 years of experience as a senior executive in the  pharmaceutical and biotech industry. He retired in January of 2005  from the position of Chief Operating Officer at Biogen-Idec, a major  global biotech company. He played an instrumental role in the $6.8  billion merger of IDEC Pharmaceuticals and Biogen Inc. Prior to  serving as COO of the combined company, Bill was the President and  Chief Operating Officer of IDEC Pharmaceuticals where he helped  transform IDEC from a small research organization into a very  successful, biotechnology company. Before moving to the fledgling  biotech industry, Bill spent approximately 25 years in the  pharmaceutical sector in a variety of commercial operating roles of  increasing responsibilities at Abbott Laboratories, Bristol-Myers  Squibb Co., and Adria Laboratories (now part of Pfizer). In addition to  his role at Protox, Bill serves on the Board of Directors of Cerus  Corporation, Intellikine, Cebix Inc., and the La Jolla Institute of  Allergy and Immunology.  Amit Sobti is a principal with Warburg Pincus where he focuses on  investments in healthcare. Prior to joining Warburg Pincus, he worked  at Rhône Capital, a mid-market private equity firm, and at Merrill  Lynch in the Mergers & Acquisitions group. Amit received an A.B. in  Business Economics and an A.B. in Computer Science from Brown  University. In addition to Protox, Amit also serves on the Board of  Directors of ReSearch Pharmaceutical Services, Inc.  About Protox Protox Therapeutics is a leader in advancing novel, receptor targeted  therapeutic fusion proteins. Two drug candidates derived from the  company's INxin™ and PORxin™ platforms are in clinical development.  Protox's lead program, PRX302 (PORxin), achieved positive results from  its Phase 2b placebo controlled trial called TRIUMPH, to treat benign  prostatic hyperplasia (BPH or enlarged prostate). Protox has partnered  with Kissei Pharmaceuticals for the development and commercialization  of PRX302 in Japan. PRX321 (INxin) is being developed for the treatment  of various cancers and has received Fast Track Designation and Orphan  Drug Status from the US FDA and EMEA for the treatment of primary brain  cancer. For more information, please visit www.protoxtherapuetics.com.  Certain statements included in this press release may be considered  forward-looking. Such statements involve known and unknown risks,  uncertainties and other factors that may cause actual results,  performance or achievements to be materially different from those  implied by such statements, and therefore these statements should not  be read as guarantees of future performance or results. All  forward-looking statements are based on Protox' current beliefs as well  as assumptions made by and information currently available to Protox  and relate to, among other things, anticipated financial performance,  business prospects, strategies, regulatory developments, market  acceptance and future commitments. Readers are cautioned not to place  undue reliance on these forward-looking statements, which speak only as  of the date of this press release. Due to risks and uncertainties,  including the risks and uncertainties identified by Protox in its  public securities filings; actual events may differ materially from  current expectations. Protox disclaims any intention or obligation to  update or revise any forward-looking statements, whether as a result of  new information, future events or otherwise.  To view this news release in HTML formatting, please use the following URL:  http://www.newswire.ca/en/releases/archive/February2011/22/c4751.html  For further information: <table border="0" valign="top"><tr><td>James Beesley<br/> Investor  Relations<br/> Protox Therapeutics<br/> 604-813-0133<br/> <a  href="mailto:jbeesley@protoxtherapeutics.com">jbeesley@protoxtherapeutics.com</a></td> <td></td> <td></td>  <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Michael Moore<br/> Investor Relations<br/>  Equicom Group<br/> 619-467-7067<br/> <a  href="mailto:mmoore@equicomgroup.com">mmoore@equicomgroup.com</a></td></tr></table>  CO: Protox Therapeutics Inc. ST: British Columbia NI: MTC 2575 WNEWS